TNF inhibitors can be used after JAK inhibitors

People with an insufficient response to adalimumab or upadacitinib achieved better responses after switching to the alternative. Introduction Rheumatoid arthritis is a chronic inflammatory disease that affects a person’s joints, causing pain and disability. Rheumatoid arthritis affects people of all ages, and is more common in women than men. Treatments for rheumatoid arthritis aim to […]

Read More…

Switch to baricitinib delivers results with no need for washout

Switching from adalimumab to baricitinib delivers improvements in disease control, physical function and pain within 12 weeks, without additional side effects. Introduction Rheumatoid arthritis is a chronic inflammatory disease that affects a person’s joints, causing pain and disability. It can also affect internal organs. Rheumatoid arthritis is more common in older people and it affects […]

Read More…

Unmet needs remain in rheumatology

Defining unmet needs that can stimulate research into understanding diseases better and lead to the development of new targeted therapies, disease prevention and ultimately cure remains a priority in rheumatology. Introduction Rheumatology is a field of medicine that studies and treats people with various conditions that affect their joints, bones, tendons, ligaments and muscles – […]

Read More…

New medicines for Lupus should also be tested in children with Lupus

Innovative new trial designs mean it will be possible to test new medicines in rare diseases such as childhood Lupus. Introduction Systemic lupus erythematosus (often called Lupus or SLE) is an autoimmune disease. It typically affects women between the ages of 15 and 45, but can start in younger children. There are many things that […]

Read More…

Risk of some types of serious bacterial infection are higher with tocilizumab than TNFi

Serious bacterial infection, skin and soft tissue infection, and diverticulitis are more common with tocilizumab than TNFi, but there is no overall difference in the rates of serious infection including bacterial, viral or opportunistic infection. Introduction Rheumatoid arthritis is a chronic inflammatory disease that affects a person’s joints, causing pain and disability. It can also […]

Read More…

Risk of side effects increased in people from certain racial or ethnic backgrounds

Allopurinol should be used with caution in people with Black, Asian, or Native Hawaiian/Pacific Islander heritage. Introduction Gout is a very common condition. It is caused by deposits of crystals of a substance called uric acid (also known as urate) in the joints, which leads to inflammation. Periods of time when you have gout symptoms […]

Read More…

Tailored treatment may be a possibility for AAV in people with GPA or MPA

AAV relapse rates did not significantly differ between individually tailored and fixed schedule rituximab regimens. Introduction Granulomatosis is a medical term for a disease where granulomas – or clusters of certain cell types – are formed. This can happen in immune or inflammatory diseases. People can have with granulomatosis with polyangiitis (also known as Wegener’s […]

Read More…

Managing fibromyalgia

This is the patient version of the EULAR recommendations for the management of fibromyalgia. The original publication can be downloaded from the EULAR website: www.eular.org. Macfarlane GJ, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017;76(2):318–328. doi:10.1136/annrheumdis-2016-209724 Introduction EULAR recommendations give advice to doctors, nurses and patients about the best […]

Read More…

Endpoint not met, but golimumab delivers improvement in JIA

Golimumab results in rapid improvement in children with active polyarticular JIA INTRODUCTION Juvenile idiopathic arthritis, commonly referred to as JIA, includes most types of arthritis seen in children before the age of 16. JIA is an umbrella term for a group of inflammatory arthritis conditions with unknown cause which begin in childhood. JIA causes pain, […]

Read More…